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NALP1 (also called DEFCAP, NAC, CARD7) has been shown
to play a central role in the activation of inflammatory caspases
and processing of pro-IL1β (pro-interleukin-1β). Previous studies
showed that NALP1 is highly expressed in peripheral blood
mononuclear cells. In the present study, we report that expression
of NALP1 is absent from CD34+ haematopoietic blast cells,
and its levels are upregulated upon differentiation of CD34+
cells into granulocytes and to a lesser extent into monocytes.
In peripheral blood cells, the highest levels of NALP1 were
observed in CD3+ (T-lymphocytes), CD15+ (granulocytes) and
CD14+ (monocytes) cell populations. Notably, the expression of
NALP1 was significantly increased in the bone marrow blast
cell population of some patients with acute leukaemia, but not
among tissue samples from thyroid and renal cancer. A search for
consensus sites within the NALP1 promoter revealed a sequence
for CREB (cAMP-response-element-binding protein) that was
required for transcriptional activity. Moreover, treatment of TF1
myeloid leukaemia cells with protein kinase C and protein kinase
A activators induced CREB phosphorylation and upregulated
the mRNA and protein levels of NALP1. Conversely, ectopic
expression of a dominant negative form of CREB in TF1 cells
blocked the transcriptional activity of the NALP1 promoter and
significantly reduced the expression of NALP1. Thus NALP1
is transcriptionally regulated by CREB in myeloid cells, a
mechanism that may contribute to modulate the response of these
cells to pro-inflammatory stimuli.
Key words: blast cell, cAMP-response-element-binding protein
(CREB), inflammation, leukaemia, NALP1, tumour cell.
INTRODUCTION
NALP1 (also called DEFCAP, NAC and CARD7) belongs to
a newly identified family of cytoplasmic proteins that have been
implicated in cell responses to apoptotic and inflammatory stimuli
[1–3]. Two major isoforms have been identified for NALP1 which
differ in a sequence of 132 bp that encodes an LRR (leucine-rich
repeat) near the 3′ end of the coding region [2]. NALP1 has been
shown to interact with caspases 5, -1, -2, -9 and Apaf1 [2–4],
thus participating in the cytochrome c-mediated activation of
apoptotic caspases, as well as in the activation of inflammatory
caspases.
NALP1 differs from the other NALP proteins in that it con-
tains a CARD (caspase-recruitment domain). CARD-containing
proteins, including Apaf1, Ced-4, Nod1 and Nod2, are involved
in the regulation of apoptotic and/or inflammatory responses.
All these proteins have been grouped into the so-called CATER-
PILLER family, containing CARD, pyrin, nucleotide-binding and
LRR domains [5]. Nod proteins have been shown to recognize
bacterial components, including LPS (lipopolysaccharides)
and/or bacterial muramyl dipeptide [6,7], and this interaction
leads to the activation of NF-κB (nuclear factor κB), a trans-
cription factor that plays a central role in innate immunity and
cell survival [8,9]. Interestingly, mutations in the coding region of
Nod2 have been associated with susceptibility to Crohn’s disease
and Blau syndrome, two chronic inflammatory disorders [10–12].
Furthermore, patients with hereditary fever syndromes and chro-
nic inflammatory diseases, such as Muckle–Wells syndrome and
familial cold urticaria, who carry mutations in the coding sequence
of NALP3 have been identified recently [13]. Of note, these
mutations are clustered in a highly conserved domain that shares
significant similarity with NALP1.
Very little is known about the transcriptional regulation of
NALPs and other genes of the CATERPILLER family. Of note,
induction of Apaf1 mRNA and protein expression has been shown
to be dependent on the transcriptional activity of p53 [14]. More
recently, it has been described that Nod2 expression is enhanced
by pro-inflammatory cytokines and bacterial components via
NF-κB, a mechanism that may contribute to the amplification
of the innate immune response [15]. Furthermore, much remains
to be discovered to further elucidate the expression and function
of these genes within the haematopoietic compartment. A detailed
expression pattern in the different haematopoietic compartments
has only been established for Nod2. This gene is expressed upon
differentiation of CD34+ cells into granulocyte or monocyte/
macrophages, and the highest levels were detected in mature
myelomonocytes [15]. Previous studies showed that NALP1 is
highly expressed in peripheral blood mononuclear cells [2,3]. In
the present study we report that NALP1 is absent from CD34+
blast cells, but readily detected in T-lymphocytes, monocytes and
granulocytes. Of note, the levels of NALP1 increased in bone
marrow samples from some patients with acute leukaemia, but
not in samples of solid tumours. Moreover, we have demonstrated
that induction of NALP1 by a PKC (protein kinase C) activator or
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cAMP analogues is mediated through CREB (cAMP-response-




Human leukaemia cell lines TF1 and K562 were maintained in
RPMI 1640 medium (Seromed Biochrom KG, Berlin, Germany)
supplemented with 10% fetal calf serum (Flow Laboratories,
Irvine, CA, U.S.A.) and 5 ng/ml of recombinant human IL-3
(interleukin-3) (Immunex, Seattle, WA, U.S.A.).
Mobilized peripheral blood progenitors were obtained from
normal donors undergoing mobilization for allogeneic pro-
genitor cell transplantation, as described previously [15]. Purified
CD34+ cells (more than 95%) were seeded into 24-well cul-
ture plates at 5 × 104 cells/ml in Iscove’s modified Dulbecco’s
medium (Invitrogen, Carlsbad, CA, U.S.A.), containing 20%
fetal calf serum and recombinant human SCF (stem cell factor),
IL-3 and IL-6 (Immunex) at a final concentration of 100 ng/ml.
Granulocyte and monocyte/macrophage cell populations were
generated as described previously [15].
Mononuclear cells obtained from bone marrow of patients with
acute leukaemia and snap-frozen tissue from patients with dif-
ferent solid tumours were analysed for the expression of NALP1
by real-time PCR.
All patients and normal donors gave their written informed
consent according to Guidelines from the Committee for the
Protection of Human Subjects at the Clinica Universitaria de
Navarra.
TF1 cells were treated with PMA, db-cAMP (dibutyryl-cAMP)
or staurosporine (all from Sigma, St. Louis, MO, U.S.A.) for the
various time intervals indicated.
Gene reporter assays
A genomic PCR fragment of 297 bp from the promoter region
of NALP1 (NALP1pt), was cloned into KpnI and XhoI sites of
the pGL2-basic luciferase reporter vector (Promega, Madison,
WI, U.S.A.). The authenticity of the construct was confirmed by
sequencing. TF1 cells were co-transfected with 1 µg of pGL2-
NALP1pt and 50 ng of pRSV-β-gal in triplicate by nucleofection
following the manufacturer’s instructions (Amaxa, Cologne,
Germany). When indicated, cells were co-transfected with pGL2-
NALP1pt and 1 µg of a vector containing A-CREB, a potent
and selective inhibitor of CREB DNA-binding activity [16]. Post-
transfection (24 h), cells were incubated with 50 ng/ml PMA for
6 h, and then cell extracts were prepared and analysed for the
relative luciferase activity by a dual-light reporter gene assay sys-
tem (Applied Biosystems, Foster City, CA, U.S.A.). Results
were normalized for transfection efficiency with values obtained
with pRSV-β-gal. Site-directed mutagenesis of the CRE (cAMP-
response element) site in the pGL2-NALP1pt vector was carried
out by using the QuikChange® site-directed mutagenesis kit
(Stratagene, La Jolla, CA, U.S.A.) with the following primers:
5′-CCTCTGGGGAATGTTTCCTTC-3′ and 5′-GAAGGAAAC-
ATTCCCCAGAGG-3′. The NALP1pt DNA insert was sequenced
to verify the mutation.
RT (reverse transcriptase)-PCR and RACE
(rapid amplification of cDNA ends) analysis
Total RNA was prepared using TRIzol® reagent (Invitrogen). To
assess mRNA expression, a semiquantitative RT-PCR method was
used as described previously [17]. The generated cDNA was am-
plified by using primers for human NALP1 (5′-AAGTGA-
CTGCTCCATTCGGAA-3′, and 5′-CTCCGAGAACAGCTGG-
TCTTCT-3′, located in different exons), and GAPDH (glycer-
aldehyde-3-phosphate dehydrogenase) [17]. After 20 (GAPDH)
or 30 (NALP1) amplification cycles, the expected PCR products
(205 bp for the long isoform and 73 bp for the short isoform of
NALP1) were size fractionated on a 4–20% gradient polyacry-
lamide gel and stained with ethidium bromide.
Expression data were quantified by real-time PCR in a 7000
Sequence Detection System (Applied Biosystems). The ratio of
the abundance of NALP1 transcripts to that of GAPDH transcripts
was calculated as 2n, where n is the CT (threshold cycle) value of
GAPDH minus the CT value of NALP1, and normalized by the
value of the sample with the lowest expression level of NALP1.
Specificity of the desired PCR products was determined with
melting curve analysis.
For analysis of sequences at the 5′ end of NALP1 mRNA, a
5′-RACE kit was used according to the manufacturer’s instruc-
tions (Roche, Mannheim, Germany), with the following NALP1
primers: 5′-GCTTGGTAGAGGAGTGAGGCA-3′ and 5′-CCAC-
TCGTCTTCTCTGGCTGA-3′.
Western blot analysis and antibody generation
Cell extracts (60 µg of protein) were separated on an 8% poly-
acrylamide gel, and transferred on to nitrocellulose as described
previously [17]. Blots were blocked with 3% BSA and incubated
with the corresponding primary antibodies followed by incub-
ation with goat anti-rabbit or anti-mouse antibodies conjugated to
alkaline phosphatase. Bound antibody was detected by a chem-
iluminescence system (Applied Biosystems). A polyclonal anti-
NALP1 serum was generated by repeated immunization of rabbits
with a keyhole-limpet haemocyanin-conjugated synthetic peptide
(amino acids 17–35 of NALP1). Rabbit polyclonal antibodies
against CREB and phospho-CREB were purchased from Upstate
(Charlottesville, VA, U.S.A.), and mouse anti-β-tubulin antibody
was obtained from Sigma.
EMSAs (electrophoretic mobility-shift assays)
TF1 cells were lysed and nuclear fractions were resuspended
in 20 mM Hepes, pH 7.9, 420 mM NaCl, 1 mM EDTA, 1 mM
EGTA and 20% glycerol. Nuclear extracts (5 µg of total protein)
were incubated with a 32P-labelled double-stranded DNA probe
from the promoter region of the NALP1 gene (5′-TGGGTG-
ACGTTT-3′). Samples were run on a 5% non-denaturing poly-
acrylamide gel in 200 mM Tris/borate and 2 mM EDTA. Gels
were dried and visualized by autoradiography. Supershifts were
performed using antibodies specifically against CREB, ATF1
(activating transcription factor 1) (both from Santa Cruz Biotech-
nology, Santa Cruz, CA, U.S.A.) and phospho-CREB (Upstate).
RESULTS
NALP1 is expressed in mature haematopoietic cells
NALP1 has been shown to be expressed in peripheral blood
leucocytes [18]. We aimed to extend these data by analysing
the mRNA expression of NALP1 in cells derived from in vitro-
differentiated CD34+ progenitors and in peripheral blood popu-
lations. We obtained the CD34+ cell fraction from the peripheral
blood of normal donors, and the selected population was cultured
with either G-CSF (granulocyte colony-stimulating factor) or
M-CSF (monocyte/macrophage colony-stimulating factor) to in-
duce granulocyte or monocyte/macrophage maturation, as pre-
viously described [19]. CD34+ progenitors expressed no
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Figure 1 Analysis of NALP1 mRNA in CD34+-derived cells and peripheral
blood subpopulations
Total RNA was purified from CD34+ cells cultured in the presence of M-CSF (Mo) or G-CSF
(Gr) (A and B) and from immune-purified peripheral blood cell populations (C and D), and
subjected to real-time PCR (A and C) and semiquantitative RT-PCR analysis (B and D). PCR
products were subjected to electrophoresis on a gradient polyacrylamide gel and stained with
ethidium bromide. The histograms show the means +− S.D. for triplicate analyses.
detectable levels of NALP1 mRNA, as assessed by real-time and
semiquantitative PCR (Figures 1A and 1B). However, by day 10 of
culture the expression of NALP1 was readily detectable, with the
highest levels observed in the granulocyte lineage (3-fold higher
than in monocytic cells). At day 20 of culture the expression of
NALP1 increased and the mRNA levels in granulocyte cells were
about 5-fold higher than in monocytes (Figure 1A).
Then we analysed the expression of NALP1 mRNA in peri-
pheral blood populations of B-cells (91.4% of CD19+ cells),
T-cells (99.0% of CD3+ cells), granulocytes (84.0% of CD15+
cells) and monocytes (99% of CD14+ cells) (Figures 1C and
1D). The mRNA analysis showed that B-lymphocytes express
low levels of NALP1, whereas granulocytes, monocytes and
T-lymphocytes express 16- to 23-fold as much NALP1 mRNA
as the B-cells by real-time PCR (Figure 1C). Semiquantitative
RT-PCR analyses demonstrated that the two major isoforms
of NALP1 (NALP1L and NALP1S, long and short forms res-
pectively) were present in both differentiated CD34+ cells and
peripheral blood populations. However, NALP1L consistently
gave the highest signal on gels (Figures 1B and 1D).
Differential expression of NALP1 in tumour cells
NALP1 has been shown to be highly expressed in the chronic
myeloid leukaemia cell line K562 [2]. Additionally, we have
demonstrated that NALP1 is absent in normal progenitor blast
cells (CD34+) and its levels increased along the myelomonocytic
differentiation. With this in mind, we studied the expression of
NALP1 in mononuclear cells from the bone marrow of 40 patients
with acute myeloid leukaemia (Figure 2A) or acute lymphocytic
leukaemia (Figure 2B). All selected patients had more than
80% blast cells in the bone marrow. Samples from 9 patients
showed increased mRNA levels of NALP1, and differences
among samples were as high as 60-fold. Interestingly, some
of the samples preferentially expressed the short isoform, although
the functional meaning of this pattern is presently unknown. In
view of these data, we studied the expression of NALP1 in solid
tumours. Figure 2(C) shows that the mRNA levels of NALP1
Figure 2 Expression of NALP1 in tumour cells
Total RNA was obtained from the bone marrow of patients with acute myeloid (A) or lymphocytic
(B) leukaemia and from frozen tissue sections of different solid tumours (C), and analysed for
the expression of NALP1 by real-time PCR (upper panels in A and B) and semiquantitative
RT-PCR (lower panels in A and B). PCR products were subjected to electrophoresis on a
gradient polyacrylamide gel and stained with ethidium bromide. GAPDH mRNA was used as an
amplification control. The histograms show the means +− S.D. for triplicate analyses.
were homogeneous in all samples from thyroid and renal cancer as
determined by semiquantitative RT-PCR. Furthermore, in all cases
the predominant isoform was NALP1L. These data suggest
that the differences in mRNA levels and isoforms of NALP1 are
the result of genetic and/or signalling alterations occurring prefer-
entially in haematologic malignancies such as acute leukaemia.
Promoter region of NALP1 contains a CRE consensus sequence
In order to study the transcriptional regulation of NALP1, we
first located the promoter region. A 5′-RACE analysis revealed
several transcription start sites in K562 and TF1 myeloid
leukaemia cell lines. Thus we decided to focus on the upstream
sequence from the most 5′ transcript identified in these cell
lines, which coincides with the promoter region described for
NALP1 by the Transcript Sequence Retrieval (TRASER) database
(D. Relman, Department of Microbiology and Immunology,
Stanford University, Stanford, CA, U.S.A.) (Figure 3A). We found
a putative CRE sequence 47 bases upstream from the transcription
start site (TGACGTT) that is not identical to the CRE consensus
sequence (TGACGTC). However, it is described that CREB does
not distinguish between the canonical CRE and other sequences,
even with more significant differences, such as the Ces2/E2A-
HLF-binding element (TTACGTA). Furthermore, the same CRE
sequence found in the NALP1 promoter is present in the Bcl-2
5′ region, and this site demonstrates functional activity [20]. Thus
we analysed the capacity of the CRE site to bind to CREB
protein. Nuclear extracts from TF1 cells were incubated with
a radiolabelled CRE probe from the NALP1 promoter, and then
subjected to EMSA. As shown in Figure 3(B), a single protein–
DNA complex was detected, which was supershifted in the
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Figure 3 Binding of CREB to the NALP1 promoter is increased by PMA
(A) Partial sequence of the NALP1 promoter. Putative transcription factor-binding sites
are underlined. (B) Control (Cont; untreated) or PMA-treated TF1 cells were analysed for
the formation of CREB–DNA complexes by EMSA using a radiolabelled probe from the
NALP1 promoter. Nuclear extracts were pre-incubated with antibodies (α-) specific for CREB,
phospho-CREB (pCREB) or ATF1, or with 100-fold molar excess of unlabelled CREB-specific
probe (+100xSP). (C) Cells were treated with 10 ng/ml PMA for 24 h and then total RNA was
extracted and analysed for the expression of NALP1 by real-time PCR. The histogram shows the
means +− S.D. for triplicate analyses.
presence of specific antibodies against CREB and active phospho-
CREB, but not ATF1, a transcription factor that shares high
sequence similarity with CREB, indicating that CREB specifically
binds to the sequence found in the NALP1 promoter.
It has been shown that growth factors induce CREB activation
in TF1 cells through PKC [21]. Thus we studied the effects of sti-
mulation with PMA, a PKC activator, on the expression of
NALP1 and CREB phosphorylation. PMA induced the binding
of CREB to the NALP1 promoter, as shown in Figure 3(B).
Furthermore, after 24 h of stimulation with PMA, the levels
of NALP1 mRNA in TF1 cells were increased about 2.5-fold,
as determined by real-time PCR (Figure 3C). Consistently, this
treatment resulted in the rapid phosphorylation of CREB without
a significant change in the protein levels (Figure 4A). In order
to extend the expression data to other CREB-activating stimuli,
we treated TF1 cells with db-cAMP, a cAMP analogue shown
to induce CREB phosphorylation in a number of cell systems
[22]. As expected, db-cAMP upregulated phospho-CREB in TF1
(Figure 4A). After 24 h of incubation, the NALP1 protein levels
were determined by Western blotting with an antiserum raised
against a synthetic NALP1 peptide. Specificity analyses revealed
that pre-immune sera failed to produce any signal and an NALP1-
specific neutralizing peptide abrogated the antibody reaction
(results not shown). As shown in Figure 4(B), treatment with
db-cAMP induced NALP1 protein, and the level of expression
was similar to that reached with PMA. Conversely, treatment with
the PKC inhibitor staurosporine reduced both phosphorylation of
CREB and expression of NALP1 (results not shown).
To determine whether CREB mediated the expression of
NALP1, we transfected TF1 cells with A-CREB, a dominant
negative inhibitor that functions by preventing DNA binding
of CREB in a dimerization domain-dependent fashion [16].
Figure 4 Regulation of NALP1 levels in response to CREB modulators
(A) TF1 cells were incubated with 50 ng/ml PMA (P) and 1 mM db-cAMP (dbA) and analysed for
the presence of phospho-CREB by Western blotting. The asterisk denotes a cross-reactive protein
recognized by the anti-pCREB antibody. The levels of CREB protein were also determined. Lane C,
untreated control cells. (B) Cells were cultured in the presence of 10 ng/ml PMA (P), and 1 mM
db-cAMP (dbA), and then analysed for the expression of NALP1 protein by Western blotting
with an antiserum against an NALP1 peptide. The levels of β-tubulin were also determined to
verify equal loading. (C) TF1 cell line was transiently transfected with a control vector (pCMV)
or A-CREB. After 24 h of transfection, the mRNA levels of NALP1 were determined by real-time
PCR. The histogram shows the means +− S.D. for triplicate analyses.
Figure 4(C) shows that transfection with A-CREB, but not with
vector alone, led to a significant reduction (more than 3-fold) in
the mRNA levels of NALP1 as assessed by real-time PCR.
NALP1 promoter responds to modulators of CREB activity
To study the promoter activity of the CRE sequence, a 297 bp
fragment from the promoter region of NALP1 (NALP1pt), con-
taining the CRE consensus site, was cloned into a promoterless
luciferase vector (NALP1pt-luciferase), and this construct was
transiently transfected into TF1 cells. Figure 5(A) shows a re-
presentative experiment. The levels of luciferase activity detected
in cells stimulated with PMA were significantly higher than those
observed in unstimulated cells (approx. 3.5-fold). However, this
activation was abolished in the presence of A-CREB, suggesting
that it is dependent on endogenous CREB. To further clarify the
functional specificity of the CRE site contained in the NALP1pt
fragment, a mutagenesis analysis was performed. We mutated
three bases within the sequence motif (Figure 5B) and transfected
TF1 cells with an NALP1pt mutant luciferase vector. As shown
in Figure 5(A), there were no significant differences between
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Figure 5 Transcriptional regulation of CRE-containing NALP1 promoter
(A) Cells were transfected with a wild-type NALP1 promoter fragment (NALP1pt) either alone or
with A-CREB, and a mutant NALP1 promoter [mNALP1pt; the mutation is shown in (B)], in the
presence of a constitutive β-galactosidase reporter vector (pRSV-β-gal). Cells were induced
with 50 ng/ml PMA for 6 h or left untreated. Units of luciferase activity were normalized based on
values of pRSV-β-gal activity to control for transfection efficiency. The results are expressed as
the mean +− S.D. for triplicate cultures.
the PMA-stimulated and the unstimulated cells, and in both con-
ditions the level of luciferase activity was similar to that observed
in non-transfected control cells. Thus these data show the impor-
tance of the CRE consensus site in the transcriptional activation
of NALP1 gene, and suggest a low, if any, contribution of other
putative binding sequences, at least in the cell system used here.
DISCUSSION
NALP1 is a member of the NALP protein family that shows a
domain structure similar to that found in Nod family members
[1]. Studies using genetically modified cells have revealed that
Nod1 and Nod2 activate NF-κB, a transcription factor that plays
a central role in inflammatory responses and innate immunity [8].
In the present study we show that NALP1 is upregulated during the
myelomonocytic differentiation of CD34+ progenitor cells. This
expression pattern is similar to that described previously for Nod2
[15]. Furthermore, NALP1 has been shown to be expressed in
peripheral blood mononuclear leucocytes and polymorphonuclear
cells [2,3]. We have extended these results, demonstrating that
NALP1 is mainly expressed in T-lymphocytes, granulocytes
and monocytes. However, we found an apparent discrepancy in
NALP1 expression between granulocytes and monocytes when
comparing cells obtained from peripheral blood or in vitro-derived
CD34+ progenitors. A likely explanation is that CD34+ cells
have been differentiated under the selective pressure of individual
factors (i.e., G-CSF or M-CSF), whereas peripheral blood cells
have matured under different external stimuli, including inter-
actions with stromal or other haematopoietic cells, and with an
array of growth and differentiation factors. This may lead to
differences in the expression pattern of genes targeted by the af-
fected signalling pathways. In line with this, differences in the
expression of Nod2 between CD15+ and CD14+ subpopulations
were much higher than those found between CD34-derived
granulocytes and monocytes [15]. Recent studies have shown
that NALP1 protein forms a large signal-induced multiprotein
complex that comprises caspase-1, caspase-5 and Pycard/Asc,
which plays a crucial role in the processing of pro-IL-1β [1,4].
Constitutive expression of IL-1β has been detected in many forms
of leukaemia, and, once released, it can operate in an autocrine
or paracrine manner to induce the proliferation of leukaemic
cells [23]. Interestingly, we found that the levels of NALP1
mRNA varied significantly among patients with acute myeloid or
lymphocytic leukaemia, although we could not establish a clear
correlation between NALP1 expression and disease outcome,
because of the lack of clinical data in most of the samples ana-
lysed. Of note, two major splice variants of NALP1 exist, one
of which does not contain an LRR. In line with this, it has been
described that a Nod2 variant lacking part of the LRRs, shows
a defective response to bacterial products, and is associated with
susceptibility to a chronic inflammatory bowel disease [10]. We
showed that some of the bone marrow samples from leukaemia pa-
tients mainly express the LRR-deficient isoform of NALP1. Thus,
it is tempting to speculate that this NALP1 isoform is defective
in sensing the signals triggered by external stimuli, including
pro-inflammatory molecules, and consequently leukaemic cells
carrying this variant would be less efficient in the production of
IL-1β. Further studies will be needed to determine the contri-
bution of NALP1 isoforms to the clinical course of leukaemia.
Based on the differential expression of NALP1 in different
haematopoietic cell systems, we focussed on the transcriptional
regulation of this gene, and found that CREB may be the major
transcriptional inducer of NALP1 in myeloid leukaemia cells.
Activation of CREB by phosphorylation has been shown to
upregulate the expression of the pro-inflammatory cytokine IL-6
[24], and to induce the transcriptional activation of cyclo-oxy-
genase-2, which plays a critical role in human inflammatory
disorders [25]. Thus, as described for NALP1, CREB is also
implicated in the regulation of inflammatory responses.
CREB responds to a diverse array of extracellular signals that
activate a variety of protein kinases, including PKA (protein
kinase A), MAPKs (mitogen-activated protein kinases), CaMKs
(Ca2+/calmodulin-dependent protein kinases) and PKC [26,27]. It
has been shown that IL-3 and GM-CSF (granulocyte/macrophage/
monocyte colony-stimulating factor) induce phosphorylation of
CREB in TF1 cells through PKC, indicating that, at least in
myeloid cells, PKC plays a major role in CREB activation [21].
Consistently, we have shown that treatment of leukaemic TF1
cells with the PKC activator PMA induces CREB phosphorylation
and upregulates NALP1 mRNA, and that blockade of PKC or
CREB activity reduces the expression of NALP1. In addition,
db-cAMP also induces NALP1 and phospho-CREB in TF1.
This cAMP analogue activates PKA, a key effector of cAMP-
mediated signal transduction [28]. Thus it is likely that PKA
also contributes to NALP1 expression. Nevertheless, it remains
to be elucidated whether the PKC–CREB pathway regulates the
expression of NALP1 in more physiologically relevant models,
including primary leukaemia cells.
In conclusion, we describe in the present study that CREB
activates transcription of NALP1 through signalling pathways
dependent, at least in part, on PKC in a myeloid leukaemia
cell line. This transcriptional mechanism may be involved in the
regulation of myeloid cell responses to pro-inflammatory stimuli.
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